Paper
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.
Published Oct 11, 2018 ·
The New England journal of medicine
144
Citations
5
Influential Citations
Abstract
Blood-pressure and cholesterol lowering in persons without cardiovascular disease Elevated blood pressure and elevated low-density lipoprotein (LDL) cholesterol increase the risk of cardiovascular disease. Lowering both should reduce the risk of cardiovascular events substantially. This proposition is examined in this randomised trial in which patients without cardiovascular disease were randomised to receive such treatments compared with placebos. The combination of rosuvastatin (10mg per day), candesartan (16mg per day), and hydrochlorothiazide (12.5mg per day) was associated with a significantly lower rate of cardiovascular events than dual placebo among persons at intermediate risk who did not have cardiovascular disease. Muscle weakness and dizziness were more common in the combined therapy group, but the rate of discontinuation was similar in the two groups.
RCT
Rigorous Journal
Highly CitedA combination of rosuvastatin, candesartan, and hydrochlorothiazide significantly reduces cardiovascular events in individuals at intermediate risk without cardiovascular disease, with more common side effects.
Full text analysis coming soon...